The results showed that semaglutide use was linked to an increased relative risk of ischemic optic neuropathy, but tirzepetide was not
Will this link to knee issues make insurance more likely to approve GLP-1 meds for those of us who dont have diabetes
Short-term refrigeration at 28C is acceptable, especially for reconstituted solutions
Retatrutide is a tri-agonist. It targets three distinct metabolic pathways simultaneously: The addition of Glucagon is what makes Retatrutide fundamentally different from anything currently on the market
Data backs this up, with one study finding that side effects and cost were two of the top contributors of patients who stopped taking GLP-1s for overweight or obesity within the first year of starting
(Right now, MedStockCheckr lists 17 compounding pharmacies, but it is an incomplete list.) Although we lack data on who is taking these drugs right now, the number of potential patients is vast